Cited by 112Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and Applications

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan.

Open access

Reidy-Lagunes, Diane, Pandit-Taskar, Neeta, O'Donoghue, Joseph A., Krebs, Simone, Staton, Kevin D., Lyashchenko, Serge K., Lewis, Jason S., Raj, Nitya, Gönen, Mithat, Lohrmann, Christian, Bodei, Lisa, Weber, Wolfgang A.·2019·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-19-1026PMC PMC8382090

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Abstract Purpose: Radiolabeled somatostatin receptor 2 (SSTR2) antagonists have shown higher tumor uptake and tumor-to-organ ratios than somatostatin agonists in preclinical models of neuroendocrine tumors (NETs). We performed a phase I study to evaluate the safety and efficacy of SSTR2 antagonist 177Lu-satoreotide tetraxetan. Patients and Methods: Twenty patients with advanced SSTR2-positive NETs were treated with 177Lu-satoreotide tetraxetan. Patients first underwent a dosimetry study with 177Lu-satoreotide tetraxetan to determine the therapeutic activity that could be safely administered. This activity was split into two equal cycles to be delivered 3 months apart. The maximum activity was 7.4 GBq per cycle. Results: Of 20 patients with NETs (one lung, seven small bowel, nine pancreatic, one gastric, one rectal, one kidney; mean prior treatments: three), six received one cycle of 177Lu- satoreotide tetraxetan and 14 received two cycles. Hematologic toxicity after cycle 1 was mild-moderate and reversed before cycle 2. However, grade 4 hematologic toxicity occurred in four of seven (57%) patients after cycle 2 of 177Lu-satoreotide tetraxetan. The study was suspended, and the protocol modified to limit the cumulative absorbed bone marrow dose to 1 Gy and to reduce prescribed activity for cycle 2 by 50%. The best overall response rate was 45% [5% complete response (1/20), 40% partial response (8/20)]; with 40% stable disease (8/20) and 15% progression of disease (3/20). Median progression-free survival (PFS) was 21.0 months (95% CI, 13.6–NR). Conclusions: In this trial of heavily treated NETs, preliminary data are promising for the use of 177Lu-satoreotide tetraxetan. Additional studies are ongoing to determine optimal therapeutic dose/schedule.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-1026

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Rinke, A., Müller, H., Schade‐Brittinger, C., Klose, K., Barth, P. J., Wied, M., Mayer, C., Aminossadati, B., Pape, U., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,507
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Caplin, M. E., Pavel, M. E., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L. R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316158 · Cited by 1,937
Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients
Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Oei, H. Y., van Hagen, M., Postema, P. T., de Jong, M., Reubi, J. C., et al. (1993) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/bf00181765 · Cited by 1,560
Treatment With the Radiolabeled Somatostatin Analog [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate: Toxicity, Efficacy, and Survival
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L. R., van Eijck, C. H. J., van Essen, M., Kooij, P. P. M., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,454
OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine.
Stabin, M. G., Sparks, R. B., & Crowe, E. A. (2005) · PubMed · Cited by 1,340
Treatment of the Malignant Carcinoid Syndrome
Kvols, L. K., Moertel, C. G., O’Connell, M. J., Schutt, A. J., Rubin, J., & Hahn, R. G. (1986) · New England Journal of Medicine · doi:10.1056/nejm198609113151102 · Cited by 858
Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [ 90 Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers
Imhof, A., Brunner, P., Marincek, N., Briel, M., Schindler, C., Rasch, H. F., Mäcke, H. R., Rochlitz, C. F., Müller‐Brand, J., & Walter, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.7873 · Cited by 641
Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors
Ginj, M., Zhang, H., Waser, B., Cescato, R., Wild, D., Wang, X., Érchegyi, J., Rivier, J., Mäcke, H. R., & Reubi, J. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607761103 · Cited by 526
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
Bodei, L., Kidd, M., Paganelli, G., Grana, C. M., Drozdov, I., Cremonesi, M., Lepensky, C., Kwekkeboom, D. J., Baum, R. P., Krenning, E. P., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2893-5 · Cited by 465
Self-citation

Show all 34 references

Sorted by citations

Radiopharmaceutical therapy in cancer: clinical advances and challenges
Sgouros, G., Bodei, L., McDevitt, M. R., & Nedrow, J. R. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0073-9 · Cited by 1,032
Self-citation
Radiopharmaceuticals and their applications in medicine
Zhang, S., Wang, X., Gao, X., Chen, X., Li, L., Li, G., Liu, C., Miao, Y., Wang, R., & Hu, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02041-6 · Cited by 346
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
Gleisner, K. S., Chouin, N., Gabiña, P. M., Cicone, F., Gnesin, S., Stokke, C., Konijnenberg, M., Cremonesi, M., Verburg, F. A., Bernhardt, P., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05727-7 · Cited by 284
177 Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors
Das, S., Al-Toubah, T., El-Haddad, G., & Strosberg, J. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1685381 · Cited by 135
“a phase I study of (177)Lu-OPS201 in 20 (45% PNET) refractory well-differentiated NET patients [50].”
Background
First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy
Baum, R. P., Zhang, J., Schuchardt, C., Müller, D., & Mäcke, H. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.258889 · Cited by 127
Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy
Eychenne, R., Bouvry, C., Bourgeois, M., Loyer, P., Benoist, É., & Lepareur, N. (2020) · Molecules · doi:10.3390/molecules25174012 · Cited by 133
ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy
Sgouros, G., Bolch, W. E., Chiti, A., Dewaraja, Y. K., Emfietzoglou, D., Hobbs, R. F., Konijnenberg, M., Gleisner, K. S., Strigari, L., Yen, T., et al. (2021) · Journal of the ICRU · doi:10.1177/14736691211060117 · Cited by 139
Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study
Zhu, W., Cheng, Y., Wang, X., Yao, S., Bai, C., Zhao, H., Jia, R., Xu, J., & Huo, L. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.235093 · Cited by 87
Clinical Advances and Perspectives in Targeted Radionuclide Therapy
Lepareur, N., Ramée, B., Mougin‐Degraef, M., & Bourgeois, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061733 · Cited by 86
Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose
Lawhn-Heath, C., Hope, T. A., Martinez, J., Fung, E. K., Shin, J., Seo, Y., & Flavell, R. R. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00657-4 · Cited by 77
Theranostics - a sure cure for cancer after 100 years?
Song, Y., Zou, J., Castellanos, E., Matsuura, N., Ronald, J. A., Shuhendler, A. J., Weber, W., Gilad, A. A., Müller, C., Witney, T. H., et al. (2024) · Theranostics · doi:10.7150/thno.96675 · Cited by 78
Self-citation
Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists
Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68
The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
Harris, P. E., & Zhernosekov, K. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.941832 · Cited by 65
Radiolabeled somatostatin analogs-a continuously evolving class of radiopharmaceuticals.
Fani, M., Mansi, R., Nicolas, G. P., & Wild, D. (2022) · Cancers · doi:10.3390/cancers14051172 · Cited by 56
The molecular blueprint of targeted radionuclide therapy
Primac, I., Tabury, K., Tasdogan, A., Baatout, S., & Herrmann, K. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01069-z · Cited by 63
A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours
Wild, D., Grønbæk, H., Navalkissoor, S., Haug, A. R., Nicolas, G. P., Pais, B., Ansquer, C., Beauregard, J., McEwan, A. J. B., Laßmann, M., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06383-1 · Cited by 54
Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology
Rangger, C. A., & Haubner, R. (2020) · Pharmaceuticals · doi:10.3390/ph13020022 · Cited by 51
Peptide Receptor Radionuclide Therapy
Hofland, J., Brabander, T., Verburg, F. A., Feelders, R. A., & de Herder, W. W. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac574 · Cited by 50
Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges
Refardt, J. C., Hofland, J., Antwi, K., Nicolas, G. P., Rottenburger, C., Fani, M., Wild, D., & Christ, E. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09552-x · Cited by 50
Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies
Bidakhvidi, N. A., Goffin, K. E., Dekervel, J., Baete, K., Nackaerts, K., Clément, P. M., Cutsem, E. V., Verslype, C., & Deroose, C. M. (2021) · Cancers · doi:10.3390/cancers14010129 · Cited by 51
Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists
Nock, B. A., Kanellopoulos, P., Joosten, L., Mansi, R., & Μάινα, Θ. (2023) · Pharmaceuticals · doi:10.3390/ph16050674 · Cited by 46
Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors
Calabrò, D., Argalia, G., & Ambrosini, V. (2020) · Diagnostics · doi:10.3390/diagnostics10121059 · Cited by 44
Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors
Ambrosini, V., Zanoni, L., Filice, A., Lamberti, G., Argalia, G., Fortunati, E., Campana, D., Versari, A., & Fanti, S. (2022) · Cancers · doi:10.3390/cancers14041055 · Cited by 42
Head-to-Head Comparison of 68 Ga-NODAGA-JR11 and 68 Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: Interim Analysis of a Prospective Bicenter Study
Lin, Z., Zhu, W., Zhang, J., Miao, W., Yao, S., & Huo, L. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264890 · Cited by 38
Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review
Pellat, A., & Coriat, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061677 · Cited by 37
Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors
Cives, M., Pellè, E., & Strosberg, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113655 · Cited by 37
Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of177Lu-DOTATATE in Neuroendocrine Tumors
Bodei, L., Raj, N. P., Do, R. K., Mauguen, A., Krebs, S. S., Reidy‐Lagunes, D. L., & Schöder, H. M. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264363 · Cited by 35
Self-citation
Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy
Krebs, S. S., O’Donoghue, J. A., Biegel, E., Beattie, B. J., Reidy‐Lagunes, D. L., Lyashchenko, S. K., Lewis, J. S., Bodei, L., Weber, W., & Pandit-Taskar, N. D. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04832-9 · Cited by 35
Self-citation
Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in 177Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized Treatment
Jiménez‐Franco, L. D., Glatting, G., Prasad, V., Weber, W., Beer, A. J., & Kletting, P. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.245068 · Cited by 34
Self-citation
Pretherapeutic Comparative Dosimetry of177Lu-rhPSMA-7.3 and177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
Feuerecker, B., Chantadisai, M., Allmann, A., Tauber, R., Allmann, J., Steinhelfer, L., Rauscher, I., Wurzer, A. J., Wester, H., Weber, W., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262671 · Cited by 34
Self-citation
Targeted Cancer Therapy: What’s New in the Field of Neuroendocrine Neoplasms?
Salvia, A. L., Espinosa-Olarte, P., Martínez, M. C. R., Antón-Pascual, B., & García‐Carbonero, R. (2021) · Cancers · doi:10.3390/cancers13071701 · Cited by 34
Radiolabeled Nanocarriers as Theranostics—Advancement from Peptides to Nanocarriers
Desai, P. B., Rimal, R., Sahnoun, S. E. M., Mottaghy, F. M., Möller, M., Morgenroth, A., & Singh, S. (2022) · Small · doi:10.1002/smll.202200673 · Cited by 33
Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors
Das, S., & Dasari, A. N. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211018047 · Cited by 30
Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [177Lu]Lu-OPS201 Compared to the Agonist [177Lu]Lu-DOTA-TATE
Mansi, R., Plas, P., Vauquelin, G., & Fani, M. (2021) · Pharmaceuticals · doi:10.3390/ph14121265 · Cited by 30
Multimodal Imaging of 2-Cycle PRRT with 177Lu-DOTA-JR11 and 177Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model
Albrecht, J., Exner, S., Grötzinger, C., Prasad, S., Konietschke, F., Beindorff, N., Kühl, A. A., Prasad, V., Brenner, W., & Koziolek, E. J. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.250274 · Cited by 28
Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting
Busslinger, S. D., Mapanao, A. K., Kegler, K., Bernhardt, P., Flühmann, F., Fricke, J., Zeevaart, J. R., Köster, U., van der Meulen, N. P., Schibli, R., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06827-2 · Cited by 25
177Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial
Hallqvist, A., Brynjarsdóttir, E., Krantz, T., Sjögren, M., Svensson, J., & Bernhardt, P. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268902 · Cited by 25
Molecular imaging Theranostics of Neuroendocrine Tumors
Fortunati, E., Bonazzi, N., Zanoni, L., Fanti, S., & Ambrosini, V. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2022.12.007 · Cited by 25
Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions
Pellat, A., Cottereau, A., Palmieri, L., Soyer, P. A., Marchèse, U., Brézault, C., & Coriat, R. (2021) · Cancers · doi:10.3390/cancers13102448 · Cited by 22
68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study
Kersting, D., Sandach, P., Sraieb, M., Wiesweg, M., Metzenmacher, M., Darwiche, K., Oezkan, F., Bölükbas, S., Stuschke, M., Umutlu, L., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265664 · Cited by 17
Nuclear Medicine and Radiological Imaging of Pancreatic Neuroendocrine Neoplasms: A Multidisciplinary Update
Prosperi, D., Silveri, G. G., Panzuto, F., Faggiano, A., Russo, V., Caruso, D., Polici, M., Lauri, C., Filice, A., Laghi, A., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226836 · Cited by 24
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study
Eigler, C., McDougall, L., Bauman, A., Bernhardt, P., Hentschel, M., Blackham, K. A., Nicolas, G., Fani, M., Wild, D., & Cordier, D. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266817 · Cited by 22
First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
Handula, M., Beekman, S., Konijnenberg, M., Stuurman, D. C., de Ridder, C., Bruchertseifer, F., Morgenstern, A., Denkova, A. G., de Blois, E., & Seimbille, Y. (2023) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-023-00197-0 · Cited by 21
Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update
Franco, M. D., Zanoni, L., Fortunati, E., Fanti, S., & Ambrosini, V. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01526-5 · Cited by 21
The Emergence of Somatostatin Antagonist–Based Theranostics: Paving the Road Toward Another Success?
Impériale, A., Jha, A., Meuter, L., Nicolas, G. P., Taïeb, D., & Pacák, K. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265406 · Cited by 19
Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours
Kuiper, J., Zoetelief, E., Brabander, T., de Herder, W. W., & Hofland, J. (2024) · Journal of Neuroendocrinology · doi:10.1111/jne.13469 · Cited by 18
Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors
McClellan, K. V., Chen, E. Y.-S., Kardosh, A., Lopez, C. D., Rivero, J. D., Mallak, N., Rocha, F. G., Koethe, Y., Pommier, R. F., Mittra, E., et al. (2022) · Cancers · doi:10.3390/cancers14194769 · Cited by 20
Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours
Beykan, S., Eberlein, U., Ansquer, C., Beauregard, J., Durand‐Gasselin, L., Grønbæk, H., Haug, A. R., Hicks, R. J., Lenzo, N. P., Navalkissoor, S., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06682-1 · Cited by 19
Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [64Cu]Cu-DOTA-TOC
Vahidfar, N., Farzanehfar, S., Abbasi, M., Mirzaei, S., Delpassand, E. S., Abbaspour, F., Salehi, Y., Biersack, H. J., & Ahmadzadehfar, H. (2022) · Cancers · doi:10.3390/cancers14081914 · Cited by 19
Rethinking Dosimetry: The Perils of Extrapolated External-Beam Radiotherapy Constraints to Radionuclide Therapy
Strosberg, J., Hofman, M. S., Al‐Toubah, T., & Hope, T. A. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.267167 · Cited by 16
Somatostatin receptor radionuclide therapy in neuroendocrine tumors
Haider, M., Das, S., Al‐Toubah, T., Pellè, E., El-Haddad, G. E., & Strosberg, J. (2021) · Endocrine Related Cancer · doi:10.1530/erc-20-0360 · Cited by 16
Clinical Pharmacology of Radiotheranostics in Oncology
Beek, E. T. T., Burggraaf, J., Teunissen, J. J. M., & Vriens, D. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2598 · Cited by 16
Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy
Minczeles, N. S., Hofland, J., de Herder, W. W., & Brabander, T. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01037-7 · Cited by 15
Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study
Guo, W., Wen, X., Chen, Y., Zhao, T., Liu, J., Tao, Y., Fu, H., Wang, H., Xu, W., Pang, Y., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.05.022 · Cited by 14
Head-to-Head Comparison of SSTR Antagonist [68Ga]Ga-DATA5m-LM4 with SSTR Agonist [68Ga]Ga-DOTANOC PET/CT in Patients with Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Imaging Study
Viswanathan, R., Ballal, S., Yadav, M. P., Roesch, F., Sheokand, P., Satapathy, S., Tripathi, M., Agarwal, S., Moon, E. S., & Bal, C. (2024) · Pharmaceuticals · doi:10.3390/ph17030275 · Cited by 13
Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptides—Where Are We Now
Naik, M., AL-NAHHAS, A. M., & Khan, S. R. (2022) · Cancers · doi:10.3390/cancers14030761 · Cited by 16
Direct comparison of [18F]AlF-NOTA-JR11 and [18F]AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: Antagonist versus agonist
Ahenkorah, S., Cawthorne, C., Murce, E., Deroose, C. M., Cardinaels, T., Seimbille, Y., Bormans, G. M., Ooms, M., & Cleeren, F. (2023) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2023.108338 · Cited by 13
Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells
Nguyen, N. T., Min, Y., Rivière, J., van der Garde, M., Ghosh, S. C., Bartos, L. M., Brendel, M., Bassermann, F. C., Azhdarinia, A., Weber, W., et al. (2025) · Theranostics · doi:10.7150/thno.113354 · Cited by 14
Self-citation
Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [177Lu]Lu-Satoreotide Tetraxetan and the Agonist [177Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST2-Positive Tumours
Plas, P., Limana, L., Carré, D., Thiongane, A., Raguin, O., Mansi, R., Meyer-Losic, F., & Lezmi, S. (2022) · Pharmaceuticals · doi:10.3390/ph15091085 · Cited by 10
Drug Development in Neuroendocrine Tumors: What Is on the Horizon?
García‐Álvarez, A., Cubero, J. H., & Capdevila, J. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00834-3 · Cited by 10
Diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms by nuclear medicine: Update and future perspective
Ma, X., Ding, Y., Li, W., Li, Q., & Yang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1061065 · Cited by 10
A clinical score for neuroendocrine tumor patients under consideration for Lu-177-DOTATATE therapy
Das, S., Du, L., Schad, A., Jain, S., Jessop, A., Shah, C., Eisner, D., Cardin, D. B., Ciombor, K. K., Goff, L. W., et al. (2021) · Endocrine Related Cancer · doi:10.1530/erc-20-0482 · Cited by 9
Theranostics with somatostatin receptor antagonists in SCLC: Correlation of 68 Ga-SSO120 PET with immunohistochemistry and survival
Mavroeidi, I. A., Romanowicz, A., Haake, T., Wienker, J., Metzenmacher, M., Darwiche, K., Öezkan, F., Bölükbas, S., Stuschke, M., Umutlu, L., et al. (2024) · Theranostics · doi:10.7150/thno.98819 · Cited by 8
Optimisation of radioligand therapy in neuroendocrine tumours: Current and evolving evidence
Navalkissoor, S., Gnanasegaran, G., & Grossman, A. B. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13208 · Cited by 7
Theranostic Radiopharmaceuticals of Somatostatin Receptors for Patients with Neuroendocrine Tumors: Agonists Versus Antagonists—A Systematic Review and Meta-Analysis
Wang, Q., Librizzi, D., Bagheri, S., Ebrahimifard, A., Shamami, A. H., Rinke, A., Eilsberger, F., Luster, M., & Yousefi, B. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178539 · Cited by 5
Targeted β − -Particle Plus Conversion and Auger-Electron Therapy with 161 Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study
Fricke, J. G., Westerbergh, F., McDougall, L., Favaretto, C., Christ, E., Nicolas, G. P., Geistlich, S., Schmid, D. E., Borgna, F., Fani, M., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270654 · Cited by 5
The Latest Advances in Peptide Receptor Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors
Hindié, E., Baudin, É., Hicks, R. J., & Taïeb, D. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264422 · Cited by 5
New approaches in nuclear medicine theranostics
Enke, J. S., Fenzl, L., Lapa, C., & Viering, O. (2025) · British Journal of Radiology · doi:10.1093/bjr/tqaf143 · Cited by 4
The Role of [177Lu] Lu-Satoreotide Tetraxetan in Somatostatin Receptor-Positive Neuroendocrine Tumors
Shekhda, K. M., & Navalkissoor, S. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.07.002 · Cited by 4
Molecular Imaging in neuroendocrine neoplasias
Christ, E., Wild, D., & Refardt, J. C. (2022) · La Presse Médicale · doi:10.1016/j.lpm.2022.104115 · Cited by 4
Radiolabeled somatostatin analogs for cancer treatment. Review
Тищенко, В. К., Петриев, В. М., Крылов, В. В., Власова, О. П., Шегай, П. В., Иванов, С. А., & Каприн, А. Д. (2022) · Radiation and Risk Bulletin of the National Radiation and Epidemiological Registry · doi:10.21870/0131-3878-2022-31-2-76-96 · Cited by 4
Racial, ethnic, sex, and age representation in clinical trials of radiopharmaceutical tumor therapy: a systematic review and meta-analysis
Zhao, M., Jiang, Y., Shao, T., & Tang, W. (2025) · BMC Cancer · doi:10.1186/s12885-025-14527-9 · Cited by 3
Impact of antagonist peptides and chelators on the diagnostic performance of PET/CT using gallium-68–labeled somatostatin receptor antagonists
Xing, H., Zhu, W., Cheng, Y., Yang, Q., Jia, R., Zhao, H., Bai, C., Huo, L., & Wu, W. (2022) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000101 · Cited by 3
Chinese Medical Association consensus for standardized diagnosis and treatment of pancreatic neuroendocrine neoplasms
Jiao, F., Cui, J., Fu, D., Li, Q., Wu, Z., Teng, Z., Zhang, H., Zhou, J., Zhang, Z., Chen, X., et al. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002848 · Cited by 4
Perspective of molecular imaging and peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors: where do we stand?
Zhu, W., Liu, M., & Huo, L. (2023) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000122 · Cited by 3
Theranostic Imaging and Radiopharmaceutical Therapy
Duan, H., & Iagaru, A. H. (2023) · Springer eBooks · doi:10.1007/978-3-031-39005-0_22 · Cited by 2
Recent advances and treatment strategies in liver metastasis of pancreatic neuroendocrine tumors
Guo, Z., Han, X., Chen, J., Zhang, L., Sun, J., Li, Q., Du, X., Dong, F., & Xiu, P. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10303-0 · Cited by 2
Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies
Grewal, U. S., Shaheen, S., Zhen, D. B., Mittra, E., Halfdanarson, T. R., Singh, S., & Chan, J. A. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-518934 · Cited by 2
Theranostics with Somatostatin Receptor Antagonists
Wild, D. (2024) · Springer eBooks · doi:10.1007/978-3-031-33533-4_35 · Cited by 2
State-of-the-Art Hybrid Imaging of Neuroendocrine Neoplasms
Ambrosini, V., Fortunati, E., Fanti, S., Ursprung, S., Asmundo, L., O’Shea, A., Kako, B., Lee, S. I., Furtado, F., Blake, M. A., et al. (2024) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000001594 · Cited by 2
Systemic Therapy for Pancreatic Neuroendocrine Tumors
Wheless, M. C., & Das, S. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.08.003 · Cited by 2
Case Study #6: [177Lu]Lu-DOTA-JR11: A Somatostatin Receptor Subtype 2 Antagonist for Radiopharmaceutical Therapy
Wild, D., & Fani, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-39005-0_16 · Cited by 1
Neuroendocrine Tumors
Bodei, L., Jayaprakasam, V. S., Wong, B. Z. Y., & Aparici, C. M. (2024) · PET Clinics · doi:10.1016/j.cpet.2024.06.003 · Cited by 1
Self-citation
Radionuclides for imaging and therapy in oncology
Velikyan, I. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22253-5.00026-1 · Cited by 1
177Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumors: a systematic review and meta-analysis
Wang, J., Pang, X., Lian, J., & Lu, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1758639 · Cited by 1
Clinical Applications of Theranostics
Kuten, J., Bodei, L., & Lewis, J. S. (2026) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-032-21415-7_17 · Cited by 1
Self-citation
Radionuclide‑drug conjugates in lung cancer: advances in precision therapy and clinical translation
Liu, J., Zuo, X., Yang, X., Wang, X., Gan, L., & Xue, J. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02695-6 · Cited by 1
Theranostics and Molecular-targeted Endo-radiotherapy: The Current Landscape and Future Directions
Nazar, A. K., & Basu, S. K. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000006120 · Cited by 1
Small Intestinal, Colorectal, and Appendicular Neuroendocrine Tumors
Anthony, L. B., Gupta, G., & Chauhan, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-56968-5_20 · Cited by 1
Systemic Therapy Improvements Will Render Locoregional Treatments Obsolete for Patients with Cancer with Liver Metastases
Das, S., & Berlin, J. D. (2020) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2020.08.008
Emerging Systemic Therapies for Neuroendocrine Tumors
Gupta, M., Prinzing, G., & Iyer, R. V. (2021) · Springer eBooks · doi:10.1007/978-3-030-62241-1_20
Peptide radio receptor therapy: The huff and puff strategy of neuroendocrine disease management
Bodei, L., Kidd, M. S., & Modlin, I. M. (2021) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2021.06.002
Self-citation
RECENT DEVELOPMENT OF RADIONUCLIDE-BASED IMAGING IN DIAGNOSIS AND THERAPY OF LUNG CANCER: A REVIEW
Holik, H. A., & Aristawidya, L. (2022) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2022.v14s4.pp05
Receptor-Specific Radionuclide Therapy
Lepareur, N., & Bourgeois, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_303-1
Theranostics in Neuroendocrine Tumors
Vallabhajosula, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-23205-3_21
Systemic Therapy Improvements Will Render Locoregional Treatments Obsolete for Patients with Cancer with Liver Metastases
Das, S., & Berlin, J. D. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.08.008
Neue Ansätze in der Nuklearmedizinischen Diagnostik und Therapie
Enke, J. S., Fenzl, L., Lapa, C., & Viering, O. (2025) · Angewandte Nuklearmedizin · doi:10.1055/a-2385-3757
Receptor-Specific Radionuclide Therapy
Lepareur, N., & Bourgeois, M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00773-5_303
Additional file 1 of First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
Handula, M., Beekman, S., Konijnenberg, M., Stuurman, D. C., de Ridder, C., Bruchertseifer, F., Morgenstern, A., Denkova, A. G., de Blois, E., & Seimbille, Y. (2023) · Figshare · doi:10.6084/m9.figshare.23612575
Relationship between absorbed dose and SUV derived from SPECT/CT imaging and dose-response in patients with neuroendocrine tumors treated with [¹⁷⁷Lu]Lu-DOTA-TATE
Liu, F., Yang, H., Zhang, J., Li, J., Qiao, Y., Chen, J., & Song, S. (2026) · EJNMMI Research · doi:10.1186/s13550-026-01402-2

Authors: Reidy-Lagunes, D., Pandit-Taskar, N., O'Donoghue, J. A., Krebs, S., Staton, K. D., Lyashchenko, S. K., Lewis, J. S., Raj, N., Gönen, M., Lohrmann, C., Bodei, L., & Weber, W. A.
Affiliations: 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Memorial Sloan Kettering Cancer Center (US)
3Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
ORCID: Pandit-Taskar, Neeta
Krebs, Simone
Lewis, Jason S.
Raj, Nitya
Gönen, Mithat
Bodei, Lisa
Weber, Wolfgang A.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2019-12-01
Volume: 25
Issue: 23
Pages: 6939-6947
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-19-1026
PMC: PMC8382090
OpenAlex: W2969596297
Cited by: 112
References: 34
Citations by year: 2026: 17 · 2025: 14 · 2024: 15 · 2023: 16 · 2022: 23 · 2021: 14 · 2020: 11 · 2019: 2
FWCI: 9.52
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Funders: NIH NCI (P30 CA008748, K12 CA184746)
Topics: Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords: well-differentiated neuroendocrine tumors, radiolabeled somatostatin analogs, peptide receptor radionuclide therapy, dosimetry, hematologic toxicity, bone marrow dose, progression-free survival, treatment efficacy and safety
MeSH terms: Adult, Aged, Chelating Agents, Female, Follow-Up Studies, Heterocyclic Compounds, 1-Ring, Humans, Lutetium, Male, Middle Aged, Neoplasm Metastasis, Prognosis, Radioisotopes, Octreotide, Receptors, Somatostatin, Neuroendocrine Tumors, Radiopharmaceuticals, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks